An editorial on the TAILOR trial—further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer

Worldwide, colorectal cancer (CRC) is the second most common cancer in women and the third most common cancer in men (1). In the United States, CRC continues to be a national burden with over 140,000 new cases of CRC reported in 2015 alone (2). Over the past two decades, there have been significant advances in CRC treatment resulting in an increase in the overall survival (OS) of patients diagnosed with unresectable metastatic CRC from 12 to 30 months (3).